Papatheodoridis, George V <br/><br/>
Why do I treat HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues?  [electronic resource] 

 -  Liver international : official journal of the International Association for the Study of the Liver  Feb 2013 
 - 151-6 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1478-3231 
<br/><br/><label>Standard No.: </label>10.1111/liv.12054  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antiviral Agents--adverse effects<br/>Biomarkers--blood<br/>DNA, Viral--blood<br/>Drug Resistance, Viral<br/>Hepatitis B e Antigens--blood<br/>Hepatitis B virus--drug effects<br/>Hepatitis B, Chronic--blood<br/>Humans<br/>Nucleosides--adverse effects<br/>Nucleotides--adverse effects<br/>Treatment Outcome<br/>Viral Load